Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bio-Rad Laboratories stock in Canada | $764.62

Own Bio-Rad Laboratories shares in just a few minutes.

Bio-Rad Laboratories Inc
+ $7.91 ( + 1.03%)

Bio-Rad Laboratories is a medical devices business based in the US. Bio-Rad Laboratories stocks (BIO.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $672.7 – an increase of 0.63% over the previous week. Bio-Rad Laboratories employs 7,700 staff and has a trailing 12-month revenue of around $2.9 billion.

How to buy shares in Bio-Rad Laboratories

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BIO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Bio-Rad Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Bio-Rad Laboratories's stock price?

Since the stock market crash in March caused by coronavirus, Bio-Rad Laboratories's stock price has had significant positive movement.

Its last market close was $764.62, which is 47.62% up on its pre-crash value of $400.5 and 147.15% up on the lowest point reached during the March crash when the stocks fell as low as $309.3801.

If you had bought $1,000 worth of Bio-Rad Laboratories stocks at the start of February 2020, those stocks would have been worth $897.44 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,102.71.

Bio-Rad Laboratories stock price

Use our graph to track the performance of BIO stocks over time.

Bio-Rad Laboratories shares at a glance

Information last updated 2021-10-23.
Latest market close$764.62
52-week range$507.22 - $832.70
50-day moving average $760.26
200-day moving average $687.19
Wall St. target price$856.25
PE ratio 5.6218
Dividend yield N/A (0%)
Earnings per share (TTM) $134.05

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Trading Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until December 31, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Bio-Rad Laboratories price performance over time

Historical closes compared with the close of $764.62 from 2021-10-27

1 week (2021-10-21) 0.63%
1 month (2021-09-24) -4.77%
3 months (2021-07-28) 8.31%
6 months (2021-04-28) 17.81%
1 year (2020-10-28) 36.67%
2 years (2019-10-28) 123.90%
3 years (2018-10-26) 184.47%
5 years (2016-10-28) 385.01%

Is Bio-Rad Laboratories under- or over-valued?

Valuing Bio-Rad Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Rad Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bio-Rad Laboratories's P/E ratio

Bio-Rad Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Bio-Rad Laboratories shares trade at around 6x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Bio-Rad Laboratories's PEG ratio

Bio-Rad Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.0375. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Rad Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Bio-Rad Laboratories's EBITDA

Bio-Rad Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $711.5 million.

The EBITDA is a measure of a Bio-Rad Laboratories's overall financial performance and is widely used to measure a its profitability.

Bio-Rad Laboratories financials

Revenue TTM $2.9 billion
Operating margin TTM 19.98%
Gross profit TTM $1.4 billion
Return on assets TTM 2.85%
Return on equity TTM 42.7%
Profit margin 140.48%
Book value $389.45
Market capitalisation $22.3 billion

TTM: trailing 12 months

Shorting Bio-Rad Laboratories shares

There are currently 469,192 Bio-Rad Laboratories shares held short by investors – that's known as Bio-Rad Laboratories's "short interest". This figure is 12% down from 532,999 last month.

There are a few different ways that this level of interest in shorting Bio-Rad Laboratories shares can be evaluated.

Bio-Rad Laboratories's "short interest ratio" (SIR)

Bio-Rad Laboratories's "short interest ratio" (SIR) is the quantity of Bio-Rad Laboratories shares currently shorted divided by the average quantity of Bio-Rad Laboratories shares traded daily (recently around 151352.25806452). Bio-Rad Laboratories's SIR currently stands at 3.1. In other words for every 100,000 Bio-Rad Laboratories shares traded daily on the market, roughly 3100 shares are currently held short.

However Bio-Rad Laboratories's short interest can also be evaluated against the total number of Bio-Rad Laboratories shares, or, against the total number of tradable Bio-Rad Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bio-Rad Laboratories's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Bio-Rad Laboratories shares in existence, roughly 20 shares are currently held short) or 0.0222% of the tradable shares (for every 100,000 tradable Bio-Rad Laboratories shares, roughly 22 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bio-Rad Laboratories.

Bio-Rad Laboratories's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bio-Rad Laboratories.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Bio-Rad Laboratories's total ESG risk score

Total ESG risk: 23.57

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bio-Rad Laboratories's overall score of 23.57 (as at 01/01/2019) is pretty good – landing it in it in the 28th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Bio-Rad Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Bio-Rad Laboratories's environmental score

Environmental score: 6.03/100

Bio-Rad Laboratories's environmental score of 6.03 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Bio-Rad Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Bio-Rad Laboratories's social score

Social score: 16.8/100

Bio-Rad Laboratories's social score of 16.8 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Bio-Rad Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Bio-Rad Laboratories's governance score

Governance score: 10.75/100

Bio-Rad Laboratories's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Bio-Rad Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Bio-Rad Laboratories's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Bio-Rad Laboratories scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bio-Rad Laboratories has, for the most part, managed to keep its nose clean.

Bio-Rad Laboratories share dividends

We're not expecting Bio-Rad Laboratories to pay a dividend over the next 12 months.

Have Bio-Rad Laboratories's shares ever split?

Bio-Rad Laboratories's shares were split on a 2:1 basis on 8 March 2002. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Bio-Rad Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Bio-Rad Laboratories shares which in turn could have impacted Bio-Rad Laboratories's share price.

Bio-Rad Laboratories share price volatility

Over the last 12 months, Bio-Rad Laboratories's shares have ranged in value from as little as $507.22 up to $832.7. A popular way to gauge a stock's volatility is its "beta".

BIO.US volatility(beta: 0.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bio-Rad Laboratories's is 0.8873. This would suggest that Bio-Rad Laboratories's shares are less volatile than average (for this exchange).

Bio-Rad Laboratories overview

Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site